Business Context and Reporting Period
This Form 8-K is filed by Big Rock Partners Acquisition Corp. (BRPA) on April 19, 2021. The filing serves as a Regulation FD disclosure regarding a proposed business combination between BRPA and NeuroRx, Inc. (NRX). Under the Agreement and Plan of Merger, a wholly-owned subsidiary of BRPA will merge with NeuroRx, resulting in NeuroRx becoming a wholly-owned subsidiary of BRPA. The filing also references a press release from NeuroRx concerning a collaboration with Relief Therapeutics Holding AG for the development of ZYESAMI (aviptadil).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either BRPA or NeuroRx. This document is a current report focused on the announcement of the merger agreement and a specific corporate development, rather than a periodic financial report.
Material Changes
- Merger Agreement: BRPA and NeuroRx have entered into a definitive merger agreement.
- Collaboration Announcement: NeuroRx announced a collaboration with Relief Therapeutics Holding AG for the development of ZYESAMI (aviptadil).
Guidance, Outlook, Risks, and Contingencies
Forward-Looking Statements: The filing contains forward-looking statements regarding the proposed transaction and NeuroRx's drug development pipeline. Management cautions that actual results may differ materially from expectations.
Key Risks and Uncertainties:
- Approval, timing, and ability to complete the proposed business combination.
- BRPA's ability to remain listed on the Nasdaq Capital Market prior to and after the closing of the transaction.
- Inherent uncertainty associated with the FDA approval process for NeuroRx's drugs.
- Potential disruption of NeuroRx's current plans and operations due to the transaction.
- Costs related to the proposed business combination.
- Impact of COVID-19 or other adverse public health developments.
Additional Information: Investors are urged to read the Registration Statement on Form S-4, which includes the preliminary proxy statement, prospectus, and consent solicitation statement, for detailed information on the proposed transactions.
Important Facts for Investor Verification
- Verify the terms of the merger agreement and the expected timeline for closing.
- Review the Form S-4 registration statement for detailed financial projections and risk factors.
- Confirm the status of the collaboration with Relief Therapeutics Holding AG and the development stage of ZYESAMI (aviptadil).
- Monitor the voting process for BRPA stockholders regarding the proposed business combination.
- Assess the risks associated with FDA approval for NeuroRx's drug candidates.